Cleveland Clinic Taussig Cancer Institute
Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.
- 2024 Management of Checkpoint Inhibitor-Related Toxicity
- 8th Annual Cleveland Breast Cancer Summit
- 2024 ASH Review
- 2023 Breast Cancer Update: Review of Breast Cancer Symposia
- 2023 Management of Checkpoint Inhibitor-Related Toxicity
- 2022 Management of Checkpoint Inhibitor-Related Toxicities
- 2022 Breast Cancer Update: Review of Breast Cancer Symposium
- 2021 Management of Checkpoint Inhibitor-Related Toxicity
- Breast Cancer Update: Review of Breast Cancer Symposia
- 7th Annual Multidisciplinary Colorectal Oncology Course
- ASCO 2020 Highlights
- 20th Annual ASH Review
- 2020 Management of Checkpoint Inhibitor-Related Toxicity
- 2020 Multidisciplinary Head and Neck Cancer Update
- 6th Annual Multidisciplinary Colorectal Oncology Course
- 5th Annual Cleveland Breast Cancer Summit
- 5th Annual Multidisciplinary Colorectal Oncology Course
- Breast
- GI
- GU
- Skin
- Lymphoma
- Leukemia
- Lung
- Gyn
- MDS/MPN
- Benign Hematology
- Myeloma
- Hematologic Malignancies
- Events
- Updates in Melanoma and High Risk Skin Cancer Management
Playback speed
10 seconds
R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
By
Cleveland Clinic Taussig Cancer Institute
FEATURING
Brian Hill
By
Cleveland Clinic Taussig Cancer Institute
FEATURING
Brian Hill
46 views
June 25, 2024
Chapters
Frontline Therapy & Early Treatment Results
00:00
Sequencing After Frontline Therapy & Double Refractory Challenges
02:47
Real-World Outcomes for Double Refractory CLL/SLL
05:45
Overcoming Resistance: Combination Therapy & CAR-T Options
06:35
Evaluating PI3 Kinase Inhibitors & Alternative Treatments
08:59
Introducing Pirtobrutinib: An FDA-Approved Therapy
11:02
Pirtobrutinib Efficacy & Subgroup Response Analysis
16:16
Login to view comments.
Click here to Login
Hematologic Malignancies